about
MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapyRituximab (Rituxan) therapy for severe thyroid-associated ophthalmopathy diminishes IGF-1R(+) T cellsFibroblasts expressing the thyrotropin receptor overarch thyroid and orbit in Graves' disease.Increased expression of TSH receptor by fibrocytes in thyroid-associated ophthalmopathy leads to chemokine production.CD40 Expression in Fibrocytes Is Induced by TSH: Potential Synergistic Immune Activation.Interleukin-6 production in CD40-engaged fibrocytes in thyroid-associated ophthalmopathy: involvement of Akt and NF-κB.The Impact of Radiation Oncologists on the Early Adoption of Hypofractionated Radiation Therapy for Early-Stage Breast Cancer.Geographic Disparity in the Use of Hypofractionated Radiation Therapy Among Elderly Women Undergoing Breast Conservation for Invasive Breast CancerPathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer.The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells.Modern Radiation Therapy and Cardiac Outcomes in Breast Cancer.Obesity and angiolymphatic invasion in primary breast cancer.Multi-institutional Randomized Trial Testing the Utility of an Interactive Three-dimensional Contouring Atlas Among Radiation Oncology Residents.Truthfulness in patient-reported outcomes: factors affecting patients' responses and impact on data quality
P50
Q28259779-B88373B2-0265-42DD-81AC-7BBF0409B1ADQ35443741-94D5E094-9283-4945-913C-470D70A309F8Q35597978-2DEB8040-1188-4707-98D9-0A3B23738E6AQ35921354-C81CFC2B-D104-4D1B-B545-C406D7277406Q36133982-43E8D156-4B1C-4B07-9886-E53C74CFA5EDQ36422528-0C5AD74D-A03D-4578-8DC4-CA611A686FB5Q38765417-CDBE731F-DBFC-4081-ADA2-5FFCD637B626Q38912981-405EF06C-BB93-4D6D-9342-73B471BD4ED2Q39456208-62BF2301-4B41-46FB-B2AA-3CA2ECA99949Q39855685-9FFE952F-63CF-43DC-8782-8DFFEAD4B31EQ39924030-4985B272-C08F-4F04-9D81-A8AC3486719AQ43245975-0086DEFF-5365-4290-B612-FDD41E4DA91EQ45930443-85857570-5259-4D08-AD54-6313C14B683BQ92237283-7692C43E-6238-4BDB-8D07-E43009A9BF88
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
E Gillespie
@ast
E Gillespie
@en
E Gillespie
@es
E Gillespie
@nl
type
label
E Gillespie
@ast
E Gillespie
@en
E Gillespie
@es
E Gillespie
@nl
prefLabel
E Gillespie
@ast
E Gillespie
@en
E Gillespie
@es
E Gillespie
@nl
P106
P31
P496
0000-0002-1386-1542